

**Company registration number: 377794**

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Financial statements**

**for the financial year ended 31 December 2016**

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Contents**

	<b>Page</b>
Directors and other information	<b>1</b>
Directors report	<b>2 - 4</b>
Directors responsibilities statement	<b>5</b>
Independent auditor's report to the members	<b>6 - 7</b>
Profit and loss account	<b>8</b>
Statement of income and retained earnings	<b>9</b>
Balance sheet	<b>10</b>
Statement of cash flows	<b>11</b>
Notes to the financial statements	<b>12 - 16</b>

**Medical Research Charities CLG**  
**Company limited by guarantee**

**Directors and other information**

<b>Directors</b>	Philip Watt Catherine O'Connor Vincent McCabe Áine Kelly Tony Heffernan Avril Kennan John McCormack Peter Murphy Suzanne McCormack Anne Marie O'Dowd
<b>Secretary</b>	Catherine O'Connor
<b>Company number</b>	377794
<b>Registered office</b>	Digital Office Centre 12 Camden Row Dublin 8
<b>Business address</b>	Digital Office Centre 12 Camden Row Dublin 8
<b>Auditor</b>	McCloskey & Co Apex Business Centre Blackthorn Road Sandyford Dublin 18
<b>Bankers</b>	AIB 7/12 Dame Street Dublin 2

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Directors report**

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2016.

**Directors**

The names of the persons who at any time during the financial year were directors of the company are as follows:

Philip Watt  
Catherine O'Connor  
Vincent McCabe  
Áine Kelly  
Tony Heffernan  
Avril Kennan  
John McCormack  
Peter Murphy  
Suzanne McCormack  
Anne Marie O'Dowd

**Principal activities**

The main objects of the company are to inform, facilitate and support those charities in Ireland that are undertaking medical research in the development of their research function.

The activities are funded by the receipt of grants, awards, donations, member subscriptions or through fundraising.

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Directors report (continued)**

**Development and performance**

The MRCG, IPPOSI and GRDO co-hosted Rare Disease Day in Dublin Castle on Feb 29th. Approx 120 people attended including patients, clinicians, pharmaceutical industry representatives and policy makers. The topics covered included i) Rare Disease Policy and ii) The use of technology within the rare disease community.

The MRCG hosted the fourth Irish Health Research Forum in May at the Gibson Hotel with over 80 people in attendance. The theme of the Forum was "How can legislation facilitate health research?" Beth Thompson of the Wellcome Trust was the keynote speaker.

The MRCG hosted a conference on Promoting Public and Patient Involvement in Research on Tuesday, 27th September in the Irish Aviation Authority. Keynote speaker was Explorer and Collaboration Catalyst, Mark Pollock.

A round of the MRCG/HRB Joint Funding Scheme was completed in June 2016 whereby the HRB and MRCG members jointly agreed funding awards for research projects over 3 years to the total value of approx. €1.6 million.

The MRCG were awarded €242,344 from Pobal (through the SSNO scheme) to fund 2 part-time staff over 3 years starting July 1st 2016

The MRCG were funded €50,000 from the HRB from Sep 2016 which provided for a consultant to develop a new MRCG strategy and business plan and also contributed to core funding. We have also agreed a multiannual award from the HRB of €75,000 per annum from Jan 2017 will run until June 2020.

**Principal risks and uncertainties**

The Directors have identified that the key risks and uncertainties the company faces relate to the risk of reduced funding in the future and of the potential increase in compliance requirements in accordance with company, health and safety, taxation and other legislation;

The company mitigates these risks as follows: i) The company continually monitors the level of activity, prepares and monitors its budgets targets and projections. ii) The company closely monitors emerging changes to regulations and legislation on an ongoing basis.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with health and safety of staff.

**Likely future developments**

The company plans continuing the activities outlined above in the forthcoming years subject to satisfactory funding arrangements.

**Financial instruments**

**Accounting records**

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at the registered office.

**Relevant audit information**

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Directors report (continued)**

**Auditors**

In accordance with Section 383 (2) of Companies Act 2014, the auditors, McCloskey & Co, have indicated their willingness to continue in office.

This report was approved by the board of directors on 7 September 2017 and signed on behalf of the board by:

Philip Watt  
Director

Vincent McCabe  
Director

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Directors responsibilities statement**

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council, and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **Independent auditor's report to the members of Medical Research Charities CLG**

We have audited the financial statements of Medical Research Charities CLG for the year ended 31 December 2016 which comprise the profit and loss account, statement of income and retained earnings, balance sheet, statement of cash flows and related notes. The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland.

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### **Respective responsibilities of directors and auditor**

As explained more fully in the directors responsibilities statement set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014. Our responsibility is to audit and express an opinion on the financial statements in accordance with Irish law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors, including "APB Ethical Standard - Provisions Available for Small Entities (Revised)", in the circumstances set out below:

As a small entity under the provisions of the APB in relation to Ethical Standards we engage our auditor to assist with the preparation of the financial statements.

### **Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the directors report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

### **Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2016 and of its loss for the year then ended; and
- have been properly prepared in accordance with the relevant reporting framework and, in particular the requirements of the Companies Act 2014.

### **Matters on which we are required to report by the Companies Act 2014**

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors report is consistent with the financial statements.

**Independent auditor's report to the members of  
Medical Research Charities CLG (continued)**

**Matters on which we are required to report by exception**

We have nothing to report in respect of our obligation under the Companies Act 2014 to report to you if, in our opinion, the disclosures of directors remuneration and transactions specified by sections 305 to 312 of the Act are not made.

Thomas McCloskey

For and on behalf of  
McCloskey & Co  
Chartered Accountants & Registered Auditor  
Apex Business Centre  
Blackthorn Road  
Sandyford  
Dublin 18

7 September 2017

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Profit and loss account**  
**Financial year ended 31 December 2016**

	<b>Note</b>	<b>2016</b> €	2015 €
<b>Turnover</b>	<b>5</b>	136,105	136,230
Direct costs		(139,135)	(170,515)
<b>Gross loss</b>		(3,030)	(34,285)
Administrative expenses		(38,571)	(18,892)
<b>Operating loss</b>	<b>6</b>	(41,601)	(53,177)
Other interest receivable and similar income	<b>8</b>	7	301
<b>Loss before taxation</b>		(41,594)	(52,876)
Tax on loss		-	-
<b>Loss for the financial year</b>		<u>(41,594)</u>	<u>(52,876)</u>

All the activities of the company are from continuing operations.

The company has no other recognised items of income and expenses other than the results for the financial year as set out above.

The notes on pages 12 to 16 form part of these financial statements.

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Statement of income and retained earnings**  
**Financial year ended 31 December 2016**

	<b>2016</b>	2015
	€	€
Loss for the financial year	(41,594)	(52,876)
<b>Retained earnings at the start of the financial year</b>	<u>105,734</u>	<u>158,610</u>
<b>Retained earnings at the end of the financial year</b>	<u><u>64,140</u></u>	<u><u>105,734</u></u>

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Balance sheet**  
**As at 31 December 2016**

	Note	2016 €	€	2015 €	€
<b>Fixed assets</b>					
Tangible assets	10	669		1,344	
			669		1,344
<b>Current assets</b>					
Debtors	11	16,786		16,675	
Cash at bank and in hand		78,416		101,050	
		95,202		117,725	
<b>Creditors: amounts falling due within one year</b>	12	(31,731)		(13,335)	
<b>Net current assets</b>			63,471		104,390
<b>Total assets less current liabilities</b>			64,140		105,734
<b>Net assets</b>			64,140		105,734
<b>Capital and reserves</b>					
Profit and loss account	15		64,140		105,734
<b>Members funds</b>			64,140		105,734

These financial statements were approved by the board of directors on 7 September 2017 and signed on behalf of the board by:

Philip Watt  
Director

Vincent McCabe  
Director

The notes on pages 12 to 16 form part of these financial statements.

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Statement of cash flows**  
**Financial year ended 31 December 2016**

	<b>2016</b>	<b>2015</b>
	<b>€</b>	<b>€</b>
<b>Cash flows from operating activities</b>		
Loss for the financial year	(41,594)	(52,876)
<i>Adjustments for:</i>		
Depreciation of tangible assets	675	972
Other interest receivable and similar income	(7)	(301)
Accrued expenses/(income)	2,323	(27,144)
<i>Changes in:</i>		
Trade and other debtors	(111)	(9,646)
Trade and other creditors	16,073	3,324
Cash generated from operations	<u>(22,641)</u>	<u>(85,671)</u>
Interest received	7	301
Net cash used in operating activities	<u>(22,634)</u>	<u>(85,370)</u>
<b>Cash flows from investing activities</b>		
Purchase of tangible assets	-	(1,100)
Net cash from/(used in) investing activities	<u>-</u>	<u>(1,100)</u>
<b>Net increase/(decrease) in cash and cash equivalents</b>	(22,634)	(86,470)
<b>Cash and cash equivalents at beginning of financial year</b>	<u>101,050</u>	<u>187,519</u>
<b>Cash and cash equivalents at end of financial year</b>	<u><u>78,416</u></u>	<u><u>101,049</u></u>

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements**  
**Financial year ended 31 December 2016**

**1. General information**

The company is a private company limited by guarantee, registered in Ireland. The address of the registered office is Digital Office Centre, 12 Camden Row, Dublin 8.

**2. Statement of compliance**

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

**3. Accounting policies and measurement bases**

**Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

**Turnover**

All incoming resources are included in the financial statements when the company is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Membership income and 5% levy income is included in full in the financial statements when receivable.

**Expenditure**

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

**Taxation**

No charge to current or deferred taxation arises as the charity has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, Charity no. CHY 15386.

**Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

**Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment                      - 33%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2016**

**Impairment**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

**Financial instruments**

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

**Defined contribution plans**

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

**4. Limited by guarantee**

The company is one limited by guarantee not having a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding €1.27.

**5. Turnover**

Turnover arises from:

	<b>2016</b>	2015
	€	€
Memberships and subscriptions	22,249	21,550
5% Levy	-	38,217
Pobal funding	58,856	64,265
Sponsorship	55,000	12,198
	<u>136,105</u>	<u>136,230</u>

The whole of the turnover is attributable to the principal activity of the company which is wholly undertaken in Ireland.

**6. Operating loss**

Operating loss is stated after charging/(crediting):

	<b>2016</b>	2015
	€	€
Depreciation of tangible assets	<u>675</u>	<u>972</u>

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2016**

**7. Staff costs**

The average number of persons employed by the company during the financial year, including the directors, was as follows:

	<b>2016</b>	2015
	<b>Number</b>	Number
Administration	3	4
	<u>          </u>	<u>          </u>

The aggregate payroll costs incurred during the financial year were:

	<b>2016</b>	2015
	<b>€</b>	€
Wages and salaries	97,648	109,283
Social insurance costs	10,473	12,264
Other retirement benefit costs	4,359	3,325
	<u>112,480</u>	<u>124,872</u>

**8. Other interest receivable and similar income**

	<b>2016</b>	2015
	<b>€</b>	€
Bank deposits	7	301
	<u>          </u>	<u>          </u>

**9. Appropriations of profit and loss account**

	<b>2016</b>	2015
	<b>€</b>	€
At the start of the financial year	105,734	158,610
Loss for the financial year	(41,594)	(52,876)
<b>At the end of the financial year</b>	<u>64,140</u>	<u>105,734</u>

**Medical Research Charities CLG**  
(A Company Limited by Guarantee and not having Share Capital)

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2016**

**10. Tangible assets**

	Fixtures, fittings and equipment €	Total €
<b>Cost</b>		
<b>At 1 January 2016 and 31 December 2016</b>	5,274	5,274
<b>Depreciation</b>		
At 1 January 2016	3,930	3,930
Charge for the financial year	675	675
<b>At 31 December 2016</b>	4,605	4,605
<b>Carrying amount</b>		
<b>At 31 December 2016</b>	669	669
At 31 December 2015	1,344	1,344

**11. Debtors**

	2016 €	2015 €
Other debtors	13,499	14,937
Prepayments	3,287	1,738
	16,786	16,675

**12. Creditors: amounts falling due within one year**

	2016 €	2015 €
Trade creditors	402	998
Tax and social insurance: PAYE and social welfare	5,116	10,827
Accruals	3,833	1,510
Deferred income	22,380	-
	31,731	13,335

**13. Employee benefits**

The amount recognised in profit or loss in relation to defined contribution plans was €4,359 (2015: €3,325).

**Medical Research Charities CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2016**

**14. Financial instruments**

The carrying amount for each category of financial instruments is as follows:

	<b>2016</b>	2015
	€	€
<b>Financial assets that are debt instruments measured at amortised cost</b>		
Other debtors	16,786	16,675
Cash at bank and in hand	78,416	101,050
	<u>          </u>	<u>          </u>
<b>Financial liabilities measured at amortised cost</b>		
Trade creditors	402	998
Other creditors	8,949	12,337
	<u>          </u>	<u>          </u>

**15. Reserves**

The profit and loss account reserves represent cumulative surpluses and deficits of the company.

**16. Approval of financial statements**

The board of directors approved these financial statements for issue on 7 September 2017.

**Medical Research Charities Limited**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2015**

**17. Grants received**

**Grant 1**

Agency	Pobal
Sponsoring Government Department	Department of the Environment, Community and Local Government
Grant Programme	Support for National Organisations
Total Grant	€139,933
Grant taken to income in the period	€64,265
Cash received in the period	€64,265
Amounts deferred or due at the period end at the period end	€0
Term	July 1 <sup>st</sup> 2014 to June 30 <sup>th</sup> 2016
Received year end	31 December 2015
Capital grant	Nil
Restriction on use	Pay and general administration

**18. Staff costs**

The number of employees whose emoluments for the year fall within the following bands are as follows:

	<b>2016</b>	2015
	<b>No.</b>	No.
€60,000 - €70,000	<b>0</b>	0
€70,000 - €80,000	<b>0</b>	0
€80,000 - €90,000	<b>0</b>	0
€90,000 - €100,000	<b>0</b>	0
€100,000 - €110,000	<b>0</b>	0
	<u>0</u>	<u>0</u>

**19. Tax clearance**

The company comply with relevant Circulars, including Circular 44/2006 "Tax Clearance Procedures Grants, Subsidies and Similar Type Payments.

***DRAFT financial statements 17 August 2017 12:37:38***

**Medical Research Charities CLG  
(A Company Limited by Guarantee and not having Share Capital)**

**The following pages do not form part of the statutory accounts.**

**Medical Research Charities CLG**  
**[ Company Limited by Guarantee and not having a Share Capital ]**  
**Appendix 1: Operating Statement**  
**Year ended 31 December 2016**

	<b>2016</b>	<b>2015</b>
	€	€
<b>Income</b>		
Membership and Subscriptions	22,249	21,550
5% Levy	0	38,217
Pfizer Sponsorship	5,000	5,000
HRB IHRF Forum Sponsorship	50,000	7,148
Pobal funding	58,856	64,265
Sundry income	0	50
Interest received	7	300
	<u>136,111</u>	<u>136,530</u>
<b>Direct Expenses</b>		
Salaries and Social Welfare Costs	66,942	77,771
SSNO costs	58,856	68,574
Rare Disease Taskforce	108	1,617
Communications Forum	5,413	2,745
Irish Health Research Forum	7,816	19,809
	<u>139,135</u>	<u>170,516</u>
<b>Overhead Expenses</b>		
Rent & rates	14,296	10,204
Insurance	497	973
Post, Printing and Stationery	932	725
Telephone and Fax	1,406	1,487
Computer/Website Costs	1,468	1,263
Accountancy	1,195	1,199
Audit	1,845	615
Travel/Subsistence	809	901
Board expenses	329	191
Bank Charges	267	227
Consultancy/Profession fees	13,670	0
Company Secretariat	492	0
Subscriptions	430	0
Depreciation	675	972
Sundry expenses	259	134
	<u>38,571</u>	<u>18,891</u>
<b>Total Expenses</b>	<u>177,706</u>	<u>189,407</u>
<b>Operating (Deficit)</b>	<u>(41,594)</u>	<u>(52,877)</u>

**Medical Research Charities CLG**  
**[ Company Limited by Guarantee and not having a Share Capital ]**  
**Appendix 2: Pobal Operating Statement**  
**Year ended 31 December 2016**

	<b>2016</b>	<b>2015</b>
	€	€
<b>Income</b>		
Pobal funding	58,856	64,265
<b>Direct Expenses</b>		
SSNO costs	<u>58,856</u>	<u>68,574</u>
 Operating surplus/(deficit)	 <u>(0)</u>	 <u>(4,309)</u>